vs
NNN REIT, INC.（NNN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
NNN REIT, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$240.4M vs $207.3M），NNN REIT, INC.净利率更高（39.1% vs -62.0%，领先101.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 4.1%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.3%）
NNN REIT是一家专业房地产投资信托机构，主要投资附带长期三净租约的餐饮类物业，交易多采用售后回租模式。公司注册地为美国马里兰州，总部位于佛罗里达州奥兰多市。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NNN vs RARE — 直观对比
营收规模更大
NNN
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出21.7%
4.1%
净利率更高
NNN
高出101.1%
-62.0%
两年增速更快
RARE
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $240.4M | $207.3M |
| 净利润 | $94.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 61.0% | -54.7% |
| 净利率 | 39.1% | -62.0% |
| 营收同比 | 4.1% | 25.9% |
| 净利润同比 | -2.6% | 3.5% |
| 每股收益（稀释后） | $0.50 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NNNRARE
| Q1 26 | $240.4M | — | ||
| Q4 25 | $238.4M | $207.3M | ||
| Q3 25 | $230.2M | $159.9M | ||
| Q2 25 | $226.8M | $166.5M | ||
| Q1 25 | $230.9M | $139.3M | ||
| Q4 24 | $218.5M | $164.6M | ||
| Q3 24 | $218.6M | $139.5M | ||
| Q2 24 | $216.8M | $147.0M |
净利润NNNRARE
| Q1 26 | $94.0M | — | ||
| Q4 25 | $96.0M | $-128.6M | ||
| Q3 25 | $96.8M | $-180.4M | ||
| Q2 25 | $100.5M | $-115.0M | ||
| Q1 25 | $96.5M | $-151.1M | ||
| Q4 24 | $97.9M | $-133.2M | ||
| Q3 24 | $97.9M | $-133.5M | ||
| Q2 24 | $106.7M | $-131.6M |
营业利润率NNNRARE
| Q1 26 | 61.0% | — | ||
| Q4 25 | 62.3% | -54.7% | ||
| Q3 25 | 64.0% | -106.9% | ||
| Q2 25 | 66.0% | -64.8% | ||
| Q1 25 | 62.3% | -102.6% | ||
| Q4 24 | 65.8% | -74.3% | ||
| Q3 24 | 65.7% | -94.6% | ||
| Q2 24 | 70.2% | -79.1% |
净利率NNNRARE
| Q1 26 | 39.1% | — | ||
| Q4 25 | 40.2% | -62.0% | ||
| Q3 25 | 42.1% | -112.8% | ||
| Q2 25 | 44.3% | -69.0% | ||
| Q1 25 | 41.8% | -108.5% | ||
| Q4 24 | 44.8% | -80.9% | ||
| Q3 24 | 44.8% | -95.7% | ||
| Q2 24 | 49.2% | -89.5% |
每股收益（稀释后）NNNRARE
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.51 | $-1.28 | ||
| Q3 25 | $0.51 | $-1.81 | ||
| Q2 25 | $0.54 | $-1.17 | ||
| Q1 25 | $0.51 | $-1.57 | ||
| Q4 24 | $0.52 | $-1.34 | ||
| Q3 24 | $0.53 | $-1.40 | ||
| Q2 24 | $0.58 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.4B | $-80.0M |
| 总资产 | $9.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NNNRARE
| Q1 26 | $4.6M | — | ||
| Q4 25 | $5.0M | $421.0M | ||
| Q3 25 | $157.9M | $202.5M | ||
| Q2 25 | $6.0M | $176.3M | ||
| Q1 25 | $5.1M | $127.1M | ||
| Q4 24 | $8.7M | $174.0M | ||
| Q3 24 | $173.5M | $150.6M | ||
| Q2 24 | $2.1M | $480.7M |
股东权益NNNRARE
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.4B | $-80.0M | ||
| Q3 25 | $4.4B | $9.2M | ||
| Q2 25 | $4.4B | $151.3M | ||
| Q1 25 | $4.4B | $144.2M | ||
| Q4 24 | $4.4B | $255.0M | ||
| Q3 24 | $4.4B | $346.8M | ||
| Q2 24 | $4.2B | $432.4M |
总资产NNNRARE
| Q1 26 | $9.4B | — | ||
| Q4 25 | $9.4B | $1.5B | ||
| Q3 25 | $9.5B | $1.2B | ||
| Q2 25 | $9.1B | $1.3B | ||
| Q1 25 | $9.0B | $1.3B | ||
| Q4 24 | $8.9B | $1.5B | ||
| Q3 24 | $8.9B | $1.5B | ||
| Q2 24 | $8.7B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流NNNRARE
| Q1 26 | — | — | ||
| Q4 25 | $667.1M | $-99.8M | ||
| Q3 25 | $218.3M | $-91.4M | ||
| Q2 25 | $119.4M | $-108.3M | ||
| Q1 25 | $203.3M | $-166.5M | ||
| Q4 24 | $635.5M | $-79.3M | ||
| Q3 24 | $206.6M | $-67.0M | ||
| Q2 24 | $120.5M | $-77.0M |
自由现金流NNNRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
自由现金流率NNNRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
资本支出强度NNNRARE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
现金转化率NNNRARE
| Q1 26 | — | — | ||
| Q4 25 | 6.95× | — | ||
| Q3 25 | 2.25× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NNN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
